Today, on December 7, 2020, Calmark Sweden AB (publ) ("Calmark") announces that persons on Board of Directors, executive management and major owners have made statements of intent to exercise their respective subscription warrants. The statements cover the subscription of approximately 911,548 shares at a subscription price of SEK 4.44, corresponding to approximately MSEK 4,047,273.12. This means that the exercise of about 37 percent of the warrants now has been pre-agreed through declarations of intent.
The statements of intent to exercise warrants have not been secured by prior transaction, bank guarantee or similar. The exercise period for the Series TO 2 B subscription warrants runs between December 4 and 16, 2020.
The following parties have made declarations of intent:
· Creades AB (publ), 637,460 shares corresponding to SEK 2,830,322.4
· OLCON Engineering Aktiebolag (Johhny Olsson), 237,488 shares corresponding to SEK 1,054,446.72
· Bengt Braun, 19,384 shares corresponding to SEK 86,064.96
· Meliorata AB, (Anna Söderlund, CEO) 11,416 shares corresponding to SEK 50,687.04
· Camilla Arneving, Marketing Director, 5,000 shares corresponding to SEK 22,200
· Stefan Blomsterberg, member of the board, 800 shares corresponding to SEK 3,552
In connection with Calmark's rights issue on December 4, 2019, Creades AB (publ) acquired 203,924 Series TO 2 B subscription warrants from the founder and Chairman of the Board Mathias Karlsson. In addition, Creades acquired 433,536 Series TO 2 B subscription warrants from the main owner Lars Wingefors, through the company Wingefors Invest AB.
Stockholm Corporate Finance AB is the financial adviser, Stenbergets Avtalslösningar AB is the legal adviser and Hagberg & Aneborn Fondkommission AB is the issuing agent in connection with the exercise of warrants.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
(c) 2020 Cision. All rights reserved., source Press Releases - English